- Home
- AEMD vs RNAZ Comparison
AEMD vs RNAZ Comparison
Compare AEMD & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEMD
- RNAZ
- Stock Information
- Founded
- AEMD 1984
- RNAZ 2016
- Country
- AEMD United States
- RNAZ United States
- Employees
- AEMD N/A
- RNAZ N/A
- Industry
- AEMD Medical/Dental Instruments
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- AEMD Health Care
- RNAZ Health Care
- Exchange
- AEMD Nasdaq
- RNAZ Nasdaq
- Market Cap
- AEMD 5.0M
- RNAZ 4.9M
- IPO Year
- AEMD N/A
- RNAZ 2021
- Fundamental
- Price
- AEMD $0.71
- RNAZ $6.16
- Analyst Decision
- AEMD Strong Buy
- RNAZ Strong Buy
- Analyst Count
- AEMD 1
- RNAZ 1
- Target Price
- AEMD $7.00
- RNAZ $20.00
- AVG Volume (30 Days)
- AEMD 1.3M
- RNAZ 3.3M
- Earning Date
- AEMD 02-12-2025
- RNAZ 03-31-2025
- Dividend Yield
- AEMD N/A
- RNAZ N/A
- EPS Growth
- AEMD N/A
- RNAZ N/A
- EPS
- AEMD N/A
- RNAZ N/A
- Revenue
- AEMD N/A
- RNAZ N/A
- Revenue This Year
- AEMD N/A
- RNAZ N/A
- Revenue Next Year
- AEMD N/A
- RNAZ N/A
- P/E Ratio
- AEMD N/A
- RNAZ N/A
- Revenue Growth
- AEMD N/A
- RNAZ N/A
- 52 Week Low
- AEMD $0.24
- RNAZ $2.66
- 52 Week High
- AEMD $1.85
- RNAZ $66.33
- Technical
- Relative Strength Index (RSI)
- AEMD 51.85
- RNAZ 50.39
- Support Level
- AEMD $0.62
- RNAZ $3.31
- Resistance Level
- AEMD $0.78
- RNAZ $16.73
- Average True Range (ATR)
- AEMD 0.06
- RNAZ 2.50
- MACD
- AEMD -0.01
- RNAZ 0.42
- Stochastic Oscillator
- AEMD 34.18
- RNAZ 23.57
About AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.